Abstract
To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P
Original language | English |
---|---|
Pages (from-to) | 335-338 |
Number of pages | 4 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 19 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 1987 |
ASJC Scopus subject areas
- Pharmacology
- Oncology
- Cancer Research